tradmap

HUM Financials Humana

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 10.9% per year over the past 5 years.
  • Net income has grown slower than revenue (-18.8% vs 10.9% per year).
  • Operating margin has contracted, at 2.1% in the latest year.
  • Free cash flow has declined 39.6% per year over the past 5 years.

Financial health

  • Total debt ($12.4B) exceeds cash ($4.2B); net debt is $8.2B.
  • Total debt has grown faster than revenue (15.3% vs 10.9% per year).
  • Operating income covered interest expense 4.3× in the latest year.
  • Total debt is 3.6× EBITDA.

Shareholder returns

  • Dividends have been paid for 15 consecutive years, consuming 36.2% of earnings and 114.7% of free cash flow.
  • The dividend has grown 5.9% per year over the past 5 years.
Revenue & net income
$0 $65B $130B 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 4% 8% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $2B $5B 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $6B $12B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$7B -$459M $6B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $129.7B $1.2B 0.0% 2.1% $375M $12.4B $4.2B
2024 $117.8B $1.2B 0.0% 2.2% $2.4B $11.1B $2.2B
2023 $106.4B $2.5B 0.0% 3.8% $3.0B $10.2B $4.7B
2022 $92.9B $2.8B 0.0% 4.1% $3.5B $9.0B $5.1B
2021 $83.1B $2.9B 0.0% 3.8% $920M $10.5B $3.4B
2020 $77.2B $3.4B 0.0% 6.5% $4.7B $6.1B $4.7B
2019 $64.9B $2.7B 0.0% 4.9% $4.5B $5.0B $4.1B
2018 $56.9B $1.7B 0.0% 5.4% $1.6B $6.1B $2.3B
2017 $53.8B $2.4B 0.0% 7.9% $3.5B $4.9B $4.0B
2016 $54.4B $614M 0.0% 3.2% $1.4B $4.1B $3.9B
2015 $54.3B $1.3B 0.0% 4.3% $345M $4.1B $2.6B
2014 $48.5B $1.1B 0.0% 4.9% $1.1B $3.8B $1.9B
2013 $41.3B $1.2B 0.0% 5.0% $1.3B $2.6B $1.1B
2012 $39.1B $1.2B 0.0% 5.2% $1.5B $2.6B $1.3B
2011 $36.8B $1.4B 0.0% 6.4% $1.7B $1.7B $1.4B

Valuation over time

How the market has priced HUM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 19.0 38.0 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 0.3 0.7 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S
Dividend yield (%)
0.0 1.0 2.1 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
Dividend yield %

Frequently asked questions

Is HUM growing its revenue and profit?

Over the past 5 years, Humana's revenue has grown 10.9% per year, and net income declined 18.8% per year. These are computed facts, not advice.

How much debt does HUM have?

As of FY2025, Humana reported $12.4B of total debt against $4.2B of cash; operating income covered interest expense 4.3×.

What is HUM's profit margin?

In FY2025, gross margin was —, operating margin 2.1%, and net margin 0.9%.

What is HUM's P/E ratio?

As of Jun '26, Humana traded at a price-to-earnings ratio of about 38.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.